Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content

  

SYMPLICITY™ BLOOD PRESSURE PROCEDURE

Benefits and risks

The Medtronic Symplicity blood pressure procedure helps manage high blood pressure (hypertension),*1–3 which is shown to lower your risk of heart attacks, strokes, and other serious health problems.4

  

Illustration of a patient lying in a hospital bed while hooked up to an ECG with a female physician standing nearby

  

Reducing hypertension can lower some of your health risks.

Reducing blood pressure by 10 mmHg can lower your risk of:

heart failure4

↓28%

cardiovascular events4

↓20%

stroke4

↓27%

Benefits

Illustrated pink and white pill in a left hand and a cup of water in a right hand

Complementary to traditional blood pressure treatment

While it may not affect how many medications you take, the Symplicity blood pressure procedure helps manage high blood pressure without adding another pill to your daily regimen.1,2

Adjunctive to blood pressure medications

The Symplicity blood pressure procedure is proven to safely help manage blood pressure in people who are taking blood pressure medication and those who are not.1,2

-16.7

mmHg

blood pressure management  in a three-year study of people who received the Symplicity procedure3

Risks

What are the risks of the Symplicity blood pressure procedure?

The Medtronic Symplicity blood pressure procedure, just like any medical procedure, has risks. It's important to talk with your doctor about the benefits and risks. 

The potential risks as well as complication rates for the Symplicity blood pressure procedure are similar to those associated with other interventional procedures.

See how it works.

Get more details about the Symplicity blood pressure procedure.

*

Includes Symplicity Spyral™

References

1

Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. June 9, 2018;391(10137):2346–2355.

2

Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. May 2, 2020;395(10234):1444–1451.

3

Mahfoud F, Mancia G, Schmieder R, et al. Blood pressure and MACE reductions after renal denervation: 3-year Global Symplicity Registry results. Presented at PCR e-course 2022.

4

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis. Lancet. March 5, 2016;387(10022):957–967.